COMPANY CONTACT:Kimberly Lee, D.O.Vice President, Corporate Strategy and CommunicationsRaptor Pharmaceutical Corp.(415) 408-6351INVESTOR CONTACT:Robert H. UhlWestwicke Partners, LLC (858) email@example.comMEDIA CONTACT:Monica MayCanale Communications(619) firstname.lastname@example.org
NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update. Dial-in InformationU.S. Dial-in Number: (888) 522-1023International Dial-in Number: (704) 815-6269Conference ID: 46079703 Replay U.S. Dial-in Number: (855) 859-2056Replay International Dial-in Number: (404) 537-3406Conference ID: 46079703 The dial-in replay will be available for seven days following the call. An audio webcast will be available online in the investor relations section of the company website at www.raptorpharma.com, with a webcast replay accessible for 90 days after the call. About Raptor Pharmaceutical Corp.Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor is leading the global commercialization of two products for orphan diseases, including PROCYSBI®, for the management of nephropathic cystinosis in adults and children ages two years and older, and QUINSAIR TM, an inhaled fluoroquinolone antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). Raptor's R&D pipeline includes RP103, known commercially as PROCYSBI®, for Huntington's disease and mitochondrial disorders, including Leigh syndrome. Raptor holds several orphan drug designations, including orphan drug exclusivity for nephropathic cystinosis in the U.S. and EU. The pipeline also includes MP-376, known commercially as QUINSAIR TM, which has Qualified Infectious Disease Product (QIDP) designation for three distinct indications: the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa, in patients with CF and in patients with non-cystic fibrosis bronchiectasis (BE), and in patients with nontuberculous mycobacteria (NTM). Raptor holds orphan drug designation in the U.S. for MP-376 for the treatment of CF, which, when added to the five years of exclusivity associated with QIDP designation, would confer 12 years of regulatory exclusivity upon FDA approval. For additional information, please visit www.raptorpharma.com. Forward Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are indicated by words or phrases such as "believes," "expects," "anticipates," "estimates," "plans," "continuing," "ongoing," "projected" and similar words or phrases and relate to future events, including statements regarding: anticipated upcoming milestones, PROCYSBI® as a treatment option for patients with nephropathic cystinosis and RP103 as a treatment option for patients with Huntington's disease and mitochondrial disorders, including Leigh syndrome, orphan drug and regulatory exclusivity for MP-376 therapy in the U.S., Raptor's plans and timing to develop MP-376 in cystic fibrosis in the U.S., bronchiectasis not associated with cystic fibrosis and potentially also nontuberculous mycobacteria and Raptor's other development programs. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the company's actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Factors which may contribute to differences in actual results include, among others: Raptor's ability to market and sell QUINSAIR TM ; continued and increased market acceptance and sales of PROCYSBI® in the U.S. and other territories; Raptor's ability to expand the use of RP103 and MP-376 and to receive regulatory approval for other indications; Raptor's reliance on single active pharmaceutical ingredient suppliers for PROCYSBI and QUINSAIR TM and other third parties in connection with drug product development; compliance with healthcare regulations, ongoing regulatory requirements and potential penalties; any serious adverse side effects associated with PROCYSBI®, QUINSAIR TM or any other future products; any product liability claims; third-party payor coverage, reimbursement and pricing for PROCYSBI®, QUINSAIR TM and future products; enacted and future healthcare legislation; Raptor's ability to obtain and maintain orphan drug or other regulatory exclusivity for PROCYSBI®, QUINSAIR TM or any other future products; the integration of European operations with U.S. operations; relationships with key scientific and medical collaborators; intellectual property protection and claims and continued license rights; and Raptor's ability to fund its operations and make required payments on its debt. Certain of these risks, uncertainties and other factors are described in greater detail in the company's filings from time to time with the Securities and Exchange Commission (SEC), which Raptor strongly urges you to read and consider, including: Raptor's annual report on Form 10-K for the twelve months ended December 31, 2015 filed with the SEC on February 26, 2016, as amended by Amendment No. 1 to Form 10-K filed with the SEC on April 29, 2016, Raptor's quarterly report on Form 10-Q for the three months ended March 31, 2016 filed with the SEC on May 5, 2016 and Raptor's other periodic reports filed with SEC, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements except as may be required by law.